Cargando…
Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122)
BACKGROUND: Current guidelines recommend using filgrastim or tbo‐filgrastim to mobilize hematopoietic progenitor cells in an autologous setting. However, previous studies have suggested other forms of granulocyte colony‐stimulating factor (G‐CSF) are equally efficacious, possibly with fewer leukaphe...
Autores principales: | Jung, Eun Hee, Byun, Ja Min, Shin, Dong‐Yeop, Do, Young Rok, Jo, Jae‐Cheol, Lee, Sang Min, Yoon, Sung‐Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166964/ https://www.ncbi.nlm.nih.gov/pubmed/36951655 http://dx.doi.org/10.1002/cam4.5657 |
Ejemplares similares
-
Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
por: Jung, Jongheon, et al.
Publicado: (2023) -
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)
por: Jung, Sung-Hoon, et al.
Publicado: (2017) -
Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies
por: Ria, Roberto, et al.
Publicado: (2014) -
Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors
por: Farhan, Roiya, et al.
Publicado: (2017) -
Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
por: Song, Ga-Young, et al.
Publicado: (2023)